Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 May 23;90(2):187-196.
doi: 10.23750/abm.v90i2.8374.

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis

Mariantonietta Pisaturo  1 , Antonio Russo  1 , Lorenzo Onorato  1 , Nicola Coppola  1   2
Affiliations
Meta-Analysis

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis

Mariantonietta Pisaturo et al. Acta Biomed. .

Abstract

Background and aims: In literature systematic data on treatment with the fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks in anti-HCV/HCV RNA positive subjects with mild fibrosis and naïve to previous Interferon free regimen are scanty. A meta-analysis has been performed to evaluate the efficacy of velpatasvir plus sofosbuvir combination in these patients.

Methods: All randomized or non-randomized studies, investigating the sustained virological response rate to sofosbuvir plus velpatasvir without ribavirin for 12 weeks in subjects naïve to previous DAA therapy and with fibrosis F0-F2 or F0-F3, were included in the meta-analysis.

Results: A total of 16 studies enrolling 4,907 subjects met the inclusion criteria and were included in this meta-analysis. The prevalence of SVR by sofosbuvir and velpatasvir was 98% (95% CI 96-99%) in the 4,907 subjects without cirrhosis. The prevalence of SVR was similar considering the 9 clinical studies and the 7 real-world studies (98%, CI 95%: 96-99% and 98%; CI 95%: 96-99%, respectively). Considering the 4 studies enrolling 1,371 subjects without advanced liver fibrosis the prevalence of SVR was also high [96% (95% CI: 94-98%)]. Data indicate a prevalence of SVR ranging to 95-100% according to the different HCV genotypes.

Conclusion: Sofosbuvir plus velpatasvir therapeutic regimen was highly effective in HCV patients without advanced liver disease naïve to previous DAA regimen independently the different HCV genotypes.

PubMed Disclaimer

Conflict of interest statement

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

Figures

Figure 1.
Figure 1.
Flow-chart of article selection
Figure 2.
Figure 2.
Meta-analysis of the prevalence of SVR in subjects without cirrhosis according to type of study
Figure 3.
Figure 3.
Meta-analysis of the prevalence of SVR in subjects without advanced fibrosis (F0-F2)
Figure 4.
Figure 4.
Meta-analysis of the prevalence of SVR in HCV genotype-1 subjects without cirrhosis
Figure 5.
Figure 5.
Meta-analysis of the prevalence of SVR in HCV genotype-2 subjects without cirrhosis
Figure 6.
Figure 6.
Meta-analysis of the prevalence of SVR in HCV genotype-3 subjects without cirrhosis
Figure 7.
Figure 7.
Meta-analysis of the prevalence of SVR in HCV genotype-6 subjects without cirrhosis
Figure 8.
Figure 8.
Funnel plot of the risk ratios vs. the reciprocal of their standard errors of all studies included in the meta-analysis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013 Apr;57:1333–42. - PubMed
    1. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461–511. - PubMed
    1. AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org .
    1. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. - PubMed
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. - PubMed